SecBot SecBot
SC 13G ·Filed Nov 6, 2026

ALDX

Aldeyra Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed11d 2h ago SEC0000312069-26-000249
Passive investor 5%+ stake
Actionable Insight • Neutral

Barclays' passive stake adds institutional credibility but does not signal activist intent. Monitor for any future 13D conversion or additional accumulation by Barclays or other large holders.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$0.6337
T+0 close · Nov 6, 2026 · via day close
Latest settled
+1.59%
T+5 · $0.6438
Vs SPY
−1.00%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $0.6337entry
  2. T+1 · 8d ago +0.36%α −2.00% · $0.6360
  3. T+5 · 4d ago +1.59%α −1.00% · $0.6438
  4. T+7 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Barclays PLC disclosed a 5.48% passive stake in Aldeyra Therapeutics via a Schedule 13G filed November 6, 2026, representing 3,310,587 common shares held as of September 30, 2026. This is a new passive filer for Aldeyra, adding to prior 13G filings by AQR Capital Management, Perceptive Advisors, and Vanguard Group.

Key Financial Metrics

Stake
5.48%
Investor
Barclays PLC

Key Facts

  • Barclays PLC reported beneficial ownership of 3,310,587 common shares of Aldeyra Therapeutics
  • Stake represents 5.48% of shares outstanding as of September 30, 2026
  • Filing is a new Schedule 13G (not an amendment), certifying passive intent under Rule 13d-1(b)
  • Barclays is a new 5%+ filer for Aldeyra; prior 13G filers include AQR Capital Management, Perceptive Advisors, and Vanguard Group

Financial Impact

3,310,587 shares valued at approximately $2.1M based on $39M market cap and 5.48% stake

ownership concentration

Risk Factors

  • No stated intent to influence management or strategy
  • Passive stake could be reduced or exited without public notice

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000312069-26-000249
Document: 0000312069-26-000249-index.html0000312069-26-000249
Document: 0000312069-26-000249.txt0000312069-26-000249

Track record

12 reports on ALDX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +59.67% at T+60 after the Aug 16, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 17, 2026today 8-K Bearish 7/10 Entry $0.6799 Now $0.6939 −2.06% settles Dec 17
  2. Nov 13, 20264d ago Insider Cluster Neutral 4/10 Entry $0.6696 Now $0.6939 +3.63% settles Dec 15
  3. Nov 12, 20265d ago SC 13G/A Bearish 5/10 Entry $0.6301 Now $0.6939 −10.13% settles Dec 11
  4. Nov 9, 20268d ago 8-K Bearish 6/10 Entry $0.6291 Now $0.6939 −10.30% settles Dec 9
  5. Nov 6, 202611d ago SC 13G Neutral 3/10 Viewing Entry $0.6337 Now $0.6939 +9.50% settles Dec 7
  6. Nov 4, 202613d ago Institutional Cluster Bearish 4/10 Entry $0.6474 Now $0.6939 −7.18% settles Dec 3
  7. Sep 29, 20267w ago 8-K Bullish 7/10 Entry $1.32 to $0.6412 Now $0.6939 −47.43% ▼ −51.42% −52.14% vs SPY
  8. Aug 16, 202613w ago Institutional Cluster Bearish 6/10 Entry $1.56 to $1.37 Now $0.6939 +55.52% ▲ +12.18% +10.20% vs SPY
  9. Jul 30, 202615w ago 8-K Neutral 2/10 Entry $1.54 to $1.49 Now $0.6939 −54.94% ▼ −3.57% −6.56% vs SPY
  10. Apr 27, 202629w ago DEFA14A Neutral 2/10 Entry $1.57 to $1.78 Now $0.6939 −55.80% ▲ +13.38% +7.91% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026